N-Terminally chemically modified protein compositions and methods

Details for Australian Patent Application No. 2004235682 (hide)

Owner Amgen Inc.

Inventors Farrar, Christine E.; Deprince, Randolf B; Gabriel, Nancy E; Kinstler, Olaf

Agent Shelston IP

Pub. Number AU-A-2004235682

Parent 21285

Filing date 7 December 2004

Wipo publication date 6 January 2005

Acceptance publication date 24 July 2008

International Classifications

C07K 014/55 Peptides having more than 20 amino acids

A61K 047/48 Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

C07K 014/53 Peptides having more than 20 amino acids

C07K 001/107 General processes for the preparation of peptides

Event Publications

23 December 2004 Complete Application Filed

6 January 2005 Application Open to Public Inspection

  Published as AU-A-2004235682

24 July 2008 Application Accepted

  Published as AU-A-2004235682

20 November 2008 Standard Patent Sealed

3 November 2011 Section 223 Application Received

  Amgen Inc. An application to extend the time from 06 May 2009 to 06 Oct 2011 in which to file an extension of term has been filed . Address for service in Australia - Shelston IP Level 21 60 Margaret Street Sydney NSW 2000

22 December 2011 Section 223 Application Allowed

  Amgen Inc. The time in which to file an extension of term has been extended to 06 Oct 2011. Address for service in Australia - Shelston IP Level 21 60 Margaret Street Sydney NSW 2000

12 January 2012 Extension of Term of Standard Patents

  Amgen Inc. The earliest first regulatory approval date provided by the patentee 26 Sep 2002 For the goods NEULASTA pegfilgrastim

2 February 2012 Extension of Term of Standard Patents

  Amgen Inc. The earliest first regulatory approval date provided by the patentee 26 Sep 2002 For the goods NEULASTA pegfilgrastim Address for service in Australia: Shelston IP Level 21 60 Margaret Street Sydney NSW 2000

14 June 2012 Extension granted

  Amgen Inc. The earliest first regulatory approval date provided by the patentee 26 Sep 2002 For the goods NEULASTA pegfilgrastim Extension of Term of patent pursuant to Section 77 expires on 26 Sep 2017

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004235683-Failed nozzle relief for a mechanically sealed refueling nozzle in a filler tube

2004235681-Ink jet ejector